瑞舒伐他汀治疗中国原发性高胆固醇血症患者疗效与安全性的系统评价

doi:10.13481/j.1671-587x.20160525

Abstract

Abstract:

Objective: To evaluate the efficacy and safety of rosuvastatin and atorvastatin in the treatment of the patients with primary hyperlipidemia in China. Methods: The related literatures in CNKI, VIP, Wanfang medicine network, PubMed/MEDLINE, CBM and Chinese dissertations full text database were retrievaled by computer from the establishment time of database to December 31,2015. Two researchers according to the inclusion and exclusion criteria independently selected the studies and extracted the data and assessed the quality of the literatures. The Revman 5.0 software was used to perform Meta analysis of all effect indicators in various groups. Results: A total of 7 randomized controlled trial(RCT) were included, and there was no significant abnormality in bias evaluation. 8 weeks after treatment, the total cholesterol(TC),triglyceride(TG),low density lipoprotein cholesterol(LDL-C) and high density lipoprotein cholesterol(HDL-C) levels of the patients in 5 mg rosuvastain group and 10 mg atorvastatin group had no significant differences between before and after treatment (P>0.05); the HDL-C levels of the patients in 10 mg rosuvastatin group and 10 mg atorvastatin group had significant differences between before and after treatment(P<0.05), but the TG, TC, and LDL-C levels had no significant differences (P>0.05); the TG, TC, LDL-C and HDL-C levels of the patients in 5 mg and 10 mg rosuvastatin groups had no significant differences between before and after treatment(P>0.05). 12 weeks after treatment, there were no significant differences in the TC and LDL-C levels between 10 mg rosuvastatin group and 10 mg atorvastatin group (P>0.05), but there were significant differences in the TG and HDL-C levels (P<0.01). The incidence of adverse reactions of the patients in three groups had no significant differences(P>0.05). Conclusion: 5 mg rosuvastatin and 10 mg atorvastatin in the treatment of the patients with primary hypercholesterolemia have similar lipid-lowering effect; with the the increase of the treatment time and the dose,10 mg rosuvastatin can obviously reduce the TG level and increase the HDL-C level of the patients, and the incidence of adverse reactions of two kinds of doses of rosuvastatin has no obvious difference.

Key words: rosuvastatain, atorvastatin, primary hyperlipidemia, systematic review, Meta-analysis

CLC Number:

R589.2

DU Biao, XIE Xingxing, ZHANG Jie, FAN Xiaodong, YE Yun. Systematic review of efficacy and safety of rosuvastatin in treatment of patients with primary hyperlipidemia in China[J].Journal of Jilin University Medicine Edition, 2016, 42(05): 968-974.

References

[1] 2014年中国胆固醇教育计划血脂异常防治建议专家组.2014年中国胆固醇教育计划血脂异常防治专家建议[J].全科医学临床与教育, 2015, 13(1):3-5,10.

[2] 赵文华, 张坚, 由悦, 等.中国18岁及以上人群血脂异常流行特点研究[J].中华预防医学杂志, 2005, 39(5):306-310.

[3] 陈志华, 张皓.低密度脂蛋白及其抗体与动脉粥样硬化的关系[J].上海第二医科大学学报, 2005, 25(6):638-642.

[4] 赵永平.血脂与动脉粥样硬化及其干预新动向[J].中国动脉硬化杂志, 2009,17(3):169-171.

[5] 汪俊军, 张春妮, 庄一义.低密度脂蛋白亚组分不同特性在动脉粥样硬化中的作用[J].中国动脉硬化杂志, 2004, 12(2):227-228.

[6] 李娇红, 李小刚.低密度脂蛋白致高脂血症及动脉粥样硬化性脑梗死的机制[J].西南军医, 2012, 14(3):518-520.

[7] Fonseca FA, Ruiz A, Cardona-Munoz EG, et al.The DISCOVERY PENTA study:a direct statin comparison of LDL-C value-an evaluation of roshuvastatin therapy compared with atorvastatin[J].Curr Med Res Opin, 2005, 21(8):1307-1315.

[8] Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus taorvastation, simvastatin, and pravastatin across doses (STELLAR×Trial)[J].Am J Cardiol, 2003, 92(2):152-160.

[9] Zhu JR, Tomlinson B, Ro YM, et al. A randomised study comparing the efficacy and safety of rosuvastatin with atorvastatin for achieving lipid goals in clinical practice in Asian patients at high risk of cardiovascular disease(DISCOVERY-Asia study)[J].Curr Med Res Opin, 2007, 23(12):3055-3068.

[10] Jüni P, Altman DG, Egger M. Systematic reviews in health care:assessing the quality of controlled clinical trials[J].BMJ, 2001, 323(7303):42-46.

[11] 吴章英, 陈君柱, 杨侃, 等.瑞舒伐他汀钙治疗原发性高胆固醇血症量效关系和安全性研究[J].中国循环杂志, 2010, 25(3):181-184.

[12] 周琳, 许嘉鸿, 宋浩明, 等.瑞舒伐他汀与阿托伐他汀治疗高胆固醇血症的疗效比较[J].同济大学学报:医学版, 2013, 34(3):93-97.

[13] 徐月萍, 孙梁燕, 邹薇, 等.不同剂量瑞舒伐他汀治疗老年高胆固醇血症的疗效和安全性比较[J].中国药业, 2013, 22(8):44-46.

[14] 荆珊, 孙宁玲, 李小鹰, 等.瑞舒伐他汀钙治疗原发性高胆固醇血症的有效性和安全性[J].中国新药杂志, 2013,22(8):937-960.

[15] 孙跃民, 姚薇, 何振山, 等.瑞舒伐他汀钙治疗原发性高胆固血症的随机双盲多中心对照研究[J].中国临床药理学杂志, 2010, 26(5):326-329.

[16] 瑞舒伐他汀中国注册临床研究协作组.瑞舒伐他汀治疗中国高胆固醇血症患者疗效和安全性的随机双盲多中心对照研究[J].中华心血管病杂志, 2007, 35(3):207-211.

[17] 曾祥广, 孔月琼, 黄红谦, 等.瑞舒伐他汀钙治疗高胆固醇血症的有效性与安全性研究[J].中国医药, 2013, 8(10):1388-1389.

[18] 全国高胆固醇血症控制状况多中心协作组.高胆固醇血症临床控制状况多中心协作研究-达标率及影响因素[J].中华心血管病杂志, 2002, 30(2):109-114.

[19] 李玉霞, 江珊.瑞舒伐他汀的研究进展[J].心血管病学进展, 2010, 31(4):585-588.

[20] 叶瑛, 贾楠.瑞舒伐他汀的临床研究进展[J].中国新药与临床杂志, 2010, 29(11):813-815.

[21] 马文学, 江志羔, 古玉燕, 等.瑞舒伐他汀和阿伐他汀对急性冠状动脉综合征患者血脂、超敏C-反应蛋白和冠状动脉支架植入术后再狭窄的影响[J].中国当代医药, 2012,19(19):30-31.

[22] 杨静, 石慧武, 魏冬梅, 等.瑞舒伐他汀对老年急性ST段抬高型心肌梗死患者急诊冠脉介入治疗术后再狭窄的影响[J].中国全科医学, 2012, 15(31):3620-3623.

[23] 陈翀昊, 王广燕, 苏衡.瑞舒伐他汀与阿托伐他汀对早发冠心病急性心肌梗死患者的近期疗效[J].中国临床药理学杂志, 2013, 29(2):126-128.

[24] 杨文, 刘洁云, 秦雷.瑞舒伐他汀与阿托伐他汀治疗冠心病的疗效对比研究[J].中国全科医学杂志, 2013, 16(2C):621-622.

[25] 高远, 关启刚, 孙宇姣, 等.急性冠脉综合征患者应用符合剂量的瑞舒伐他汀与阿托伐他汀的效果对比[J].中国医科大学学报, 2013, 42(3):235-239.

[26] 谢星星, 杜彪.喹硫平与利培酮治疗中国老年精神分裂症的系统评价[J].中国现代应用药学, 2015, 32(11):1392-1396.

[27] 杜彪, 谢星星, 张杰, 等.右旋佐匹克隆与佐匹克隆治疗失眠症的系统评价[J].药物评价研究, 2016, 39(1):112-115.

[28] 李琰, 李幼平, 兰礼吉, 等.循证医学的认识论探究[J].医学与哲学, 2014, 35(4A):1-4.

[29] 徐丽华, 闻子叶.瑞舒伐他汀降低急性冠状动脉综合征患者冠状动脉支架内再狭窄率[J].中国老年学杂志, 2016, 36(1):83-85.

Systematic review of efficacy and safety of rosuvastatin in treatment of patients with primary hyperlipidemia in China

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Metrics

Comments

Recommended 0

[1]	QI Lu, BAI Wei, YU Weiying, LI Yuanyuan, HUA Wanqing, KOU Changgui. Randomized controlled trials for curative effect of saxagliptin combined with insulin in treatment of patients with type 2 diabetes mellitus: Meta-analysis [J]. Journal of Jilin University(Medicine Edition), 2018, 44(06): 1235-1242.
[2]	NIU Huikun, QU Yangming, LI Meiqi, LI Lu, LYU Xin, SONG Yuanyuan, GAO Chunshi, LI Bo. Meta-analysis on efficacy and adverse effects of neoadjuvant chemotherapy combined with capecitabine in treatment of breast cancer [J]. Journal of Jilin University Medicine Edition, 2017, 43(06): 1171-1176.
[3]	YAO Yanan, YAO Hua, YAN Duoduo, LYU Kejia, GONG Lijun, WANG Guohua. Meta-analysis on correlation between oral lichen planus and Candida albicans infection [J]. Journal of Jilin University Medicine Edition, 2017, 43(05): 967-974.
[4]	DING Xianfei, YUAN Bo, XU Zhentao, ZHENG Shaohua, MA Yan, SHI Peina, SUN Tongwen. Dexmedetomidine and midazolam in procedural sedation:a systematic review of efficacy and safety [J]. Journal of Jilin University Medicine Edition, 2017, 43(04): 762-769.
[5]	NIU Meng, DENG Dayong, LI Yunpengfei, LIU Shuo, DING Jun. Values of MRE in diagnosis of stages of hepatic fibrosis:A Meta-analysis [J]. Journal of Jilin University Medicine Edition, 2017, 43(04): 787-793.
[6]	MA Ranyang, YU Hong, WANG Xin. Evaluation on clinical efficacy of hyperbaric oxygenation in treatment of sudden deafness:A Meta-analysis [J]. Journal of Jilin University Medicine Edition, 2017, 43(02): 298-305.
[7]	ZHANG Yang, WANG Junfeng, CAOHongyan, QIN Ling, XU Guoliang. Effectiveness and safety of Dengzhanhuasu and Dansheng Injection in treatment of patients with angina pectoris of coronary heart disease:A Meta-analysis [J]. Journal of Jilin University Medicine Edition, 2017, 43(02): 317-321.
[8]	XU Jin, CHEN Huaiji, XU Feng, WANG Qi, ZHANG Yuezhu, LIU Hongbo, ZHANG Tianrong, YE Lin. Association between phthalate ester exposure and population obesity:A Meta-analysis [J]. Journal of Jilin University Medicine Edition, 2017, 43(02): 306-310.
[9]	SUN Di, WANG Qi, CHEN Haiji, XU Feng, ZHANG Yuezhu, ZHANG Tianrong, LIU Hongbo, YE Lin. Changes of serum thyroid hormone levels in DEHP exposure population: A Meta-analysis [J]. Journal of Jilin University Medicine Edition, 2017, 43(01): 66-72.
[10]	ZHANG Chengshuai, PAN Cuiliu, GAO Yanan, HAN Bing, ZHANG Zhiru, LI Feng. Meta-analysis on influence of androgen receptor in living conditions of patients with triple-negative breast cancer [J]. Journal of Jilin University Medicine Edition, 2017, 43(01): 73-79.
[11]	LI Xingxing, TAN Jingjin, JIANG Shan, WAHG Ke. Role of let-7 and HMGA2 in occurrence and development of lung cancer: Meta-analysis [J]. Journal of Jilin University Medicine Edition, 2016, 42(06): 1116-1125.
[12]	SU Yingying, LIU Yingyu, ZHANG Yangyu, MA Yue, YANG Guang, YOU Yueyue, FU Yingli, KOU Changgui. Network Meta-analysis of 9 kinds of Chinese herb injections combined with transcatheter arterial chemoembolization in treatment of hepatocellular carcinoma [J]. Journal of Jilin University Medicine Edition, 2016, 42(06): 1126-1131.
[13]	ZU Dongni, ZHAO Mingyi, DU Wei, ZHAO Weichao, JIA Shubing, YANG Jingyu, XIANG Rongwu. Meta-analysis on safety of recombinant human brain natriuretic peptide in treatment of acute decompensated heart failure [J]. Journal of Jilin University Medicine Edition, 2016, 42(04): 768-776.
[14]	DING Xianfei, ZHOU Xueliang, DOU Mengmeng, LI Lifeng, GUO Lina, WANG Feng, FAN Qingxia. Expression of mTOR and its relationship with prognosis of breast cancer: a Meta-analysis [J]. Journal of Jilin University Medicine Edition, 2016, 42(04): 783-788.
[15]	TAO Ruying, LI Miao, ZHANG Hui. Meta-analysis on effectiveness and safety of traditional Chinese medicine combined with risperidone in treatment of schizophrenia [J]. Journal of Jilin University Medicine Edition, 2016, 42(04): 757-762.